JP2015502336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502336A5 JP2015502336A5 JP2014537254A JP2014537254A JP2015502336A5 JP 2015502336 A5 JP2015502336 A5 JP 2015502336A5 JP 2014537254 A JP2014537254 A JP 2014537254A JP 2014537254 A JP2014537254 A JP 2014537254A JP 2015502336 A5 JP2015502336 A5 JP 2015502336A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- polypeptide
- absent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 156
- 229920001184 polypeptide Polymers 0.000 claims description 109
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 109
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 109
- 238000000034 method Methods 0.000 claims description 101
- 235000001014 amino acid Nutrition 0.000 claims description 60
- 229940024606 amino acid Drugs 0.000 claims description 60
- 150000001413 amino acids Chemical class 0.000 claims description 57
- 125000000539 amino acid group Chemical group 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 43
- 102000002451 NPR2 Human genes 0.000 claims description 28
- 108010038664 atrial natriuretic factor receptor B Proteins 0.000 claims description 28
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 210000000988 bone and bone Anatomy 0.000 claims description 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 15
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 14
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 14
- 239000000692 natriuretic peptide Substances 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 14
- 235000003704 aspartic acid Nutrition 0.000 claims description 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 10
- 238000003776 cleavage reaction Methods 0.000 claims description 10
- 230000007017 scission Effects 0.000 claims description 10
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 102000005600 Cathepsins Human genes 0.000 claims description 8
- 108010084457 Cathepsins Proteins 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 3
- KJBQDYDTQCIAFO-ZLELNMGESA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O KJBQDYDTQCIAFO-ZLELNMGESA-N 0.000 claims description 2
- SEFLNGWGXSFZMH-DQZFIDPSSA-N (2s)-2-aminobutanedioic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC(O)=O SEFLNGWGXSFZMH-DQZFIDPSSA-N 0.000 claims description 2
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 claims 3
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 claims 3
- 102100025677 Alkaline phosphatase, germ cell type Human genes 0.000 claims 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 claims 2
- 101000574440 Homo sapiens Alkaline phosphatase, germ cell type Proteins 0.000 claims 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 108010031345 placental alkaline phosphatase Proteins 0.000 claims 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000022145 neurocutaneous syndrome Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 108010020346 Polyglutamic Acid Proteins 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 102000004171 Cathepsin K Human genes 0.000 description 2
- 108090000625 Cathepsin K Proteins 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 150000003355 serines Chemical class 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549047P | 2011-10-19 | 2011-10-19 | |
| US61/549,047 | 2011-10-19 | ||
| US201261649717P | 2012-05-21 | 2012-05-21 | |
| US61/649,717 | 2012-05-21 | ||
| PCT/US2012/060869 WO2013059491A1 (en) | 2011-10-19 | 2012-10-18 | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502336A JP2015502336A (ja) | 2015-01-22 |
| JP2015502336A5 true JP2015502336A5 (enExample) | 2015-12-03 |
| JP6118807B2 JP6118807B2 (ja) | 2017-04-19 |
Family
ID=48141235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537254A Active JP6118807B2 (ja) | 2011-10-19 | 2012-10-18 | アルカリホスファターゼ及び／又はナトリウム利尿ペプチドを含む組成物、並びにそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2768526B1 (enExample) |
| JP (1) | JP6118807B2 (enExample) |
| KR (1) | KR20140084201A (enExample) |
| CA (1) | CA2852874A1 (enExample) |
| ES (2) | ES2714406T3 (enExample) |
| HK (1) | HK1201446A1 (enExample) |
| SG (1) | SG11201401605QA (enExample) |
| WO (2) | WO2013058833A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| CA2823066A1 (en) * | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| CA2967851C (en) | 2014-12-05 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| JP6693134B2 (ja) * | 2015-02-02 | 2020-05-13 | 東ソー株式会社 | リンカー配列を有する抗体及びそれを用いた測定法 |
| HK1250040A1 (zh) | 2015-03-31 | 2018-11-23 | Sorriso Pharmaceuticals, Inc. | 多肽 |
| CA2981098A1 (en) * | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| JP6895421B2 (ja) | 2015-03-31 | 2021-06-30 | ブイエイチスクエアード リミテッド | ポリペプチド |
| TWI773649B (zh) | 2015-07-30 | 2022-08-11 | 美商拜奧馬林製藥公司 | Ｃ型利尿納肽變異體治療骨骼發育不良之用途 |
| RU2745528C2 (ru) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Производство щелочных фосфатаз |
| WO2017058822A1 (en) * | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| JP7613826B2 (ja) * | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| KR102449167B1 (ko) * | 2016-05-06 | 2022-09-28 | 파세비오 파마수티컬스 인코포레이티드 | 제어된 지속 방출을 위한 elp 융합 단백질 |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) * | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| AR110755A1 (es) * | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
| EP3737750B1 (en) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| US11638699B2 (en) | 2018-03-20 | 2023-05-02 | Theriva Biologics, Inc. | Intestinal alkaline phosphatase formulations |
| WO2019183209A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 糖タンパク質の製造 |
| JP2021534111A (ja) | 2018-08-10 | 2021-12-09 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法 |
| CA3137045A1 (en) | 2019-05-06 | 2020-11-12 | Synthetic Biologics, Inc. | Alkaline phosphate-based oncology treatments |
| AU2020294980A1 (en) | 2019-06-21 | 2022-02-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| EP3986931A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| US12433938B2 (en) * | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| WO2022051555A2 (en) * | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| AU2022218782A1 (en) | 2021-02-12 | 2023-08-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CA3254704A1 (en) * | 2022-03-11 | 2023-09-14 | Avirmax Biopharma Inc | COMPOSITIONS AND EXPRESSION PROCESSES OF THERAPEUTIC AGENTS |
| AR130935A1 (es) | 2022-11-02 | 2025-02-05 | Novo Nordisk As | Compuestos de cnp |
| CN116286763B (zh) * | 2023-02-28 | 2024-06-25 | 西北工业大学 | 一种热稳定性提高的胱硫醚β-合成酶突变体及应用 |
| TW202513806A (zh) * | 2023-06-07 | 2025-04-01 | 美商拜奧馬林製藥公司 | 高通量篩選與身材矮小相關之基因變異體 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352770A (en) | 1990-04-20 | 1994-10-04 | Hisayuki Matsuo | Porcine derived novel physiologically active peptide |
| JP2930380B2 (ja) | 1990-07-13 | 1999-08-03 | 壽之 松尾 | ブタ由来新規生理活性ペプチド（ｃｎｐ―５３） |
| JP3026351B2 (ja) | 1990-07-13 | 2000-03-27 | 壽之 松尾 | ブタｃｎｐ遺伝子及び前駆体蛋白 |
| JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトｃｎｐ遺伝子及び前駆体蛋白 |
| US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| WO1994020534A1 (en) | 1993-03-03 | 1994-09-15 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| US6407211B1 (en) | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| JP2002178279A (ja) | 2000-12-12 | 2002-06-25 | Ulvac Japan Ltd | 基板搬送方法 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| EP1395293B1 (en) | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentiviral vectors encoding clotting factors for gene therapy |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| KR100987360B1 (ko) | 2001-11-21 | 2010-10-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 |
| CA2433479A1 (en) | 2002-07-22 | 2004-01-22 | F. Hoffmann-La Roche Ag | Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof |
| DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| WO2005007809A2 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| EP3620530A1 (en) | 2004-03-31 | 2020-03-11 | Kazuwa Nakao | Composition for increasing body height |
| ES2465141T3 (es) | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| JP2005292718A (ja) | 2004-04-05 | 2005-10-20 | Furukawa Electric Co Ltd:The | 光導波路、光導波路モジュールおよび光導波路の作成方法 |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| JP2008521575A (ja) | 2004-12-01 | 2008-06-26 | ジェンザイム・コーポレイション | 肝臓を標的とした遺伝物質の送達方法 |
| WO2008088422A2 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| US20080181903A1 (en) | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
| PL2158319T4 (pl) * | 2007-05-11 | 2016-04-29 | Alexion Pharma Inc | Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie |
| EP2162464A1 (en) | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| PT2765139T (pt) | 2007-07-20 | 2017-07-14 | Mayo Foundation | Polipéptidos natriuréticos |
| KR20100056517A (ko) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드의 용도 |
| AR069409A1 (es) | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| HRP20161739T1 (hr) | 2009-05-20 | 2017-03-10 | Biomarin Pharmaceutical Inc. | VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa |
-
2012
- 2012-05-22 SG SG11201401605QA patent/SG11201401605QA/en unknown
- 2012-05-22 WO PCT/US2012/039004 patent/WO2013058833A1/en not_active Ceased
- 2012-05-22 CA CA2852874A patent/CA2852874A1/en not_active Abandoned
- 2012-05-22 KR KR1020147013214A patent/KR20140084201A/ko not_active Withdrawn
- 2012-10-18 ES ES12842640T patent/ES2714406T3/es active Active
- 2012-10-18 WO PCT/US2012/060869 patent/WO2013059491A1/en not_active Ceased
- 2012-10-18 ES ES18201378T patent/ES2944087T3/es active Active
- 2012-10-18 EP EP12842640.0A patent/EP2768526B1/en active Active
- 2012-10-18 HK HK15101938.6A patent/HK1201446A1/xx unknown
- 2012-10-18 JP JP2014537254A patent/JP6118807B2/ja active Active
- 2012-10-18 EP EP18201378.9A patent/EP3488861B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502336A5 (enExample) | ||
| JP2014508510A5 (enExample) | ||
| TWI619724B (zh) | 新穎之調酸素衍生物及含有該衍生物之用於治療肥胖之醫藥組成物 | |
| KR101794781B1 (ko) | 펩타이드계 ｇｌｐ－２ 작용제 | |
| EA202192588A1 (ru) | Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения | |
| JP2014526254A5 (enExample) | ||
| JP2018515088A5 (enExample) | ||
| US7638480B2 (en) | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease | |
| JP2012500001A5 (enExample) | ||
| JP2017522362A5 (enExample) | ||
| JP2019059730A (ja) | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| TW201305195A (zh) | 包含調酸素與免疫球蛋白片段之複合物及其用途 | |
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| CN102292346A (zh) | 肥胖的治疗 | |
| US12018060B2 (en) | Glucagon derivatives | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| CN104271144B (zh) | 成肌细胞分化促进剂 | |
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств | |
| JP2014516959A (ja) | トロポミオシン関連キナーゼｂレセプターに対する抗体 | |
| JP2014515595A5 (enExample) | ||
| JP2012529423A5 (enExample) | ||
| TWI361694B (en) | Use of bombesin/gastrin-releasing peptide antagonists for the treatment of sepsis or acute lung injury | |
| US11066467B2 (en) | Compositions and methods for treating ischemic heart disease | |
| CA3228429A1 (en) | Dosage regime |